World Trademark Review Recognizes Foley Attorneys and Offices in 2021 Edition of WTR 1000: The World’s Leading Trademark Practitioners
February 11, 2021
World Trademark Review
Eight Foley attorneys and three Foley offices have been named in the 2021 edition of the World Trademark Review 1000: The World’s Leading Trademark Practitioners. The WTR 1000 directory is compiled by a team of researchers based on more than 1,700 interviews with trademark practitioners and corporate counsel regarding services provided in areas such as prosecution and strategy and enforcement and litigation.
The Foley attorneys recognized include:
- Katherine Califa (prosecution and strategy)
- Mark Diliberti
- Laura Ganoza
- Jami Gekas (prosecution and strategy, enforcement and litigation)
- Rick McKenna
- Jonathan Moskin (enforcement and litigation)
- Norm Rich (prosecution and strategy)
- Robert Weisbein (prosecution and strategy, enforcement and litigation)
The Foley offices recognized include:
- District of Columbia (prosecution and strategy)
- Milwaukee
- New York (prosecution and strategy, enforcement and litigation)
For more information about WTR, please visit their website here.
People
Related News
May 1, 2026
In the News
David Rosen Weighs in on SCOTUS Review of Skinny Label Patent Dispute
Foley & Lardner LLP partner David Rosen is featured across the media for his perspective on the U.S. Supreme Court case Hikma Pharmaceuticals v. Amarin Pharma.
April 27, 2026
In the News
Jesse Neil Featured as a Distinguished Leader in Law.com's Southeastern Legal Awards
Foley & Lardner LLP partner Jesse Neil is recognized in Law.com as one of the Distinguished Leader honorees for the 2026 Southeastern Legal Awards.
April 27, 2026
In the News
David Rosen and William Holtz Analyze FDA Approval Speed, Biotech Pressures
Foley & Lardner LLP attorneys David Rosen and William Holtz are quoted in the PharmaVoice article, “FDA’s need for speed could strain small biotechs. Here’s how they can keep up,” examining the FDA’s accelerated drug approval initiatives and its impact on smaller pharmaceutical companies.